Major Update 2: Remdesivir for Adults With COVID-19: A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points.

ABSTRACT:

Background

Remdesivir is approved for the treatment of adults hospitalized with COVID-19.

Purpose

To update a living review of remdesivir for adults with COVID-19.

Data sources

Several electronic U.S. Food and Drug Administration, company, and journal websites from 1 January 2020 through 19 October 2021.

Study selection

English-language, randomized controlled trials (RCTs) of remdesivir for COVID-19.

Data extraction

One reviewer abstracted, and a second reviewer verified data. The Cochrane Risk of Bias Tool and GRADE (Grading of Recommendations Assessment, Development and Evaluation) method were used.

Data synthesis

Since the last update (search date 9 August 2021), 1 new RCT and 1 new subtrial comparing a 10-day course of remdesivir with control

SUBMITTER: Kaka AS 

PROVIDER: S-EPMC8924790 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature